The Food and Drug Administration's decision, made public on Feb. 10, to not review an application to approve Moderna's proposed mRNA-based flu vaccine set off a firestorm of criticism from public ...

Moderna seeks to return to growth Its share price has lost 90% from pandemic peaks Anti-vaccine health secretary has disrupted US vaccine policy Feb 27 (Reuters) - Europe's medicines regulator ...

Researchers at the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine) and Monash University in Australia have demonstrated that an intranasal vaccine booster may confer ...

The European Medicines Agency (EMA) announced Friday it has recommended Moderna’s combined mRNA COVID-19 and flu vaccine be granted market authorization in the European Union, marking the first time ...

The company revised its plan to seek full approval for middle-aged adults and accelerated approval for seniors. (HealthDay News) — In a sudden reversal, the U.S. Food and Drug Administration (FDA) has ...

Moderna (NASDAQ:MRNA) has agreed to pay US$950 million to resolve a long-running patent dispute tied to the technology used in its COVID-19 vaccine. The pharmaceuticals giant announced it has reached ...

Shares of Moderna on Wednesday surged to their highest in more than a year after the pharmaceutical company said it reached a deal to resolve a dispute related to its COVID vaccine. Moderna MRNA said ...

March 4 (Reuters) - Moderna (MRNA.O), opens new tab shares rose 9% on Wednesday after it settled a long-running legal battle over the technology that made its COVID-19 vaccine possible, removing an ...

A vial containing Moderna's COVID vaccine. A deal related to the vaccine's patents clears the way for the pharma company's vaccine pipeline. Shares of Moderna on Wednesday surged to their highest in ...

While the FDA has flip-flopped on whether to review Moderna’s combination influenza and COVID-19 vaccine, it’s full speed ahead for the mRNA shot in Europe. The Committee for Medicinal Products for ...

Moderna helped to rapidly create vaccines for COVID-19, leading to a financial windfall. But those vaccine sales have waned, and so has the company's top line. There are opportunities ahead for ...

European drug regulators recommended authorizing Moderna’s combined vaccine against Covid-19 and the flu, paving the way for the shot’s approval in the European Union at a time the company is facing ...